ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1155

A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis

Sheila T. Angeles-Han1, Steven Yeh2, Courtney McCracken1, Larry B. Vogler3, Kelly A. Rouster-Stevens4, Christine W. Kennedy5, Kirsten Jenkins6, Matthew Kent3, Scott Lambert7, Carolyn Drews-Botsch8 and Sampath Prahalad9, 1Emory University School of Medicine, Atlanta, GA, 2Ophthalmology, Emory University School of Medicine, Atlanta, GA, 3Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, 4Pediatric Rheumatology, Emory Univ School of Medicine, Atlanta, GA, 5Rheumatology Immunology, Emory Children's Center, Atlanta, GA, 6Children's Healthcare of Atlanta, Atlanta, GA, 7Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, 8Epidemiology, Emory University School of Public Health, Atlanta, GA, 9Pediatrics, Emory Children's Center, Atlanta, GA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: juvenile idiopathic arthritis (JIA), ocular involvement, Outcome measures, pediatric rheumatology and questionnaires

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Studies on outcomes of children with juvenile idiopathic arthritis-associated uveitis (JIA-U) focus on the clinical ocular exam and physical disability secondary to arthritis. This assessment could improve by including measures of the impact of uveitis on daily life.  However, until recently, there were no instruments that measured visual function in this population. Our objective is to validate a measure of visual function, the “Effects of Youngsters’ Eyesight on Quality of Life (QOL)” (EYE-Q), in children with uveitis.

Methods: Focus groups were held to modify the old EYE-Q for children with uveitis.  The new EYE-Q contains items specific to uveitis. A parent-proxy version was also developed.  Children with JIA, JIA-U, and idiopathic uveitis (I-U) participated.  Medical record reviews were performed. Questionnaires were completed on QOL (Pediatric QOL Inventory – PedsQL), physical function (Childhood Health Assessment Questionnaire – CHAQ), and visual function (EYE-Q). 

Results:  Participants were 104 children with JIA, 19 with JIA-U and 9 with I-U (Table 1).  There were significant differences in the child and parent EYE-Q scores in children with uveitis compared to children with JIA (Table 2).  For the child report, there were mild correlations between EYE-Q scores and logmarVA (r = -0.35) and moderate correlations with the PedsQL (r = 0.50) and CHAQ (r = -0.53) (Table 3).  Similar results were found with the parent report.  There were strong correlations between the parent and child EYE-Q (r = 0.74), and the old and new versions of the EYE-Q (r = 0.96, r = 0.94). 

Cronbach’s α for the old EYE-Q child and parent reports was 0.89.  Cronbach’s α for the new EYE-Q child report was 0.91 and for the parent report was 0.90.

Conclusion: The new EYE-Q, with items specific to uveitis, is a valid measure of visual function in children with uveitis.  There were differences in child and parent perception of disease hence the inclusion of both perspectives in disease assessment is important. The EYE-Q may be an important measure in the assessment of outcomes in this population and a better measure than the clinical exam and arthritis specific measures alone. Longitudinal studies examining the performance of the EYE-Q in children with JIA-U and I-U are ongoing. 

Table 1. Characteristics of children with JIA-associated uveitis, JIA alone, and idiopathic uveitis

JIA alone

N = 104

JIA-U

N = 19

I-U

N = 9

Demographic Characteristics

     Age, mean years + SD

     Gender, female, N (%)

     Hispanic, N (%)

 

11.6±4.8

74 (71.8)

10 (9.7)

 

10.5±4.5

16 (84.2)

4 (22.2)

 

11.7±4.9

5 (55.6)

0 (0)

Disease characteristics

   Age at arthritis onset, mean years ±SD

   Age at uveitis onset, mean years ±SD

   Duration of JIA, mean years ±SD

   Duration of uveitis, mean years ±SD

 

7.4±4.5

 

3.99±3.51

 

4.0±4.6

6.8±5.1

6.48±3.74

3.68±3.56

 

 

8.0±4.4

 

3.65±3.12

Ophthalmology exam, most recent

    LogMarVA mean±SD, worse eye

    Intraocular pressure, worse eye

    Slit lamp exam, worse eye

        Cells

              0 (<1 cell in field)

              0.5+ (1-5 cells in field)

              1+ (6-15 cells in field)

              2+ (16-25 cells in field)

              3+ (26-50 cells in field)

              4+ (>50 cells in field)

 

Complications, N (%)

   Cataracts

   Glaucoma

   Synechiae

   Band keratopathy

   Cystoid macular edema

   Other complications

 

Surgeries, N (%)

   Cataract extraction

   Periocular steroid injection

   Other ocular surgeries

N = 34

0.17±0.24

11.5 (7.8)

 

 

34

0

0

0

0

0

 

 

N = 15

0.24±0.22

19.0 (7.5)

 

 

11

2

1

2

0

0

 

N = 17

5 (29.4)

0 (0)

6 (36.3)

2 (11.8)

0 (0)

3 (17.7)

 

 

0 (0)

2(11.8)

1 (5.9)

N = 7

0.74±0.98

18.7 (8.6)

 

 

4

2

0

0

0

0

 

N = 9

6 (66.7)

2 (22.2)

7 (77.8)

5 (55.6)

3 (33.3)

4 (57.1)

 

 

3 (33.3)

3 (33.3)

2 (22.2)

Table 2. Mean scores on standard quality of life and function measures in JIA

JIA

N = 102

JIA-U

N = 19

I-U

N = 9

P value

Child Reports+

   EYEQa (range 0-4)**

   CHAQb (range 0-3)++

   PedsQLc Physical scale (range 0-100)**

   PedsQL Psychosocial scale

   PedsQL Total scale

 

Parent Reports

   EYEQa (range 0-4)**

   CHAQb (range 0-3)++

   PedsQLc Physical scale (range 0-100)**

   PedsQL Psychosocial scale

   PedsQL Total scale

 

3.64 ± 0.44

0.59 ± 0.61

70.3 + 24.4

74.5+18.8

73.1 + 19.5

 

 

3.78 ± 0.37

0.57 ± 0.63

69.48 + 25.44

76.29 + 20.15

73.83 + 20.49

 

3.31 ± 0.44

0.72 +0.67

60.47 + 24.7

69.0 +17.9

65.98 + 18.90

 

 

3.37 ± 0.57

0.56 +0.62

67.29 + 22.57

67.75 + 19.99

67.64 + 19.50

 

3.37 ± 0.79

0.00 ± 0.00

91.5 ±5.3

81.8 ±18.4

85.31 ± 18.89

 

 

3.33 ± 0.89

0.08 ± 0.17

98.2 ± 3.54

84.29 ±23.80

89.13 ± 15.42

 

0.043*

0.046*

0.023*

0.334

0.102

 

 

0.002*

0.077

0.010

0.135

0.061

+ – data are missing

ANOVA , *p-value <0.05

aEffects of Youngsters Eyesight on QOL; bChildhood Health Assessment Questionnaire; cPediatric Quality of Life Inventory

**Greater scores indicate better QOL; ++Greater scores indicate worse QOL

Table 3. Correlations of the EYEQ with standard measures of quality of life and function in JIA

R [95% CI]**

P value

EYEQa child

     LogmarVAb

     CHAQc

     PedsQLd Total scale

     EYEQ parent

     New EYE-Q

 

EYEQa parent

     LogmarVAb

    CHAQc score

    PedsQLd  total

    New EYEQa

 

-0.35  [-0.60 – (-0.03)]

-0.53 [ -0.78- (-0.57)]

 0.50 [0.33-0.63]

 0.74 [0.63 – 0.81]

 0.96 [0.94 – 0.97]

 

 

-0.22  [-0.46 – 0.046]

-0.34  [-0.48 – (-0.18)]

 0.43  [0.28 – 0.57]

 0.94  [0.916 – 0.96]

 

0.029*

<0.0001*

<0.0001*

<0.0001*

 <0.0001*

 

 

0.101

<0.001*

<0.001*

<0.001*

Spearman’s correlation coefficients, *p-value <0.05

** Mild correlations: R <0.3; Moderate correlations: R = 0.3 - 0.7; Strong correlation: R = >0.7

aEffects of Youngsters Eyesight on QOL; bLogmar visual acuity; cChildhood Health Assessment Questionnaire; dPediatric Quality of Life Inventory


Disclosure:

S. T. Angeles-Han,
None;

S. Yeh,
None;

C. McCracken,
None;

L. B. Vogler,
None;

K. A. Rouster-Stevens,
None;

C. W. Kennedy,
None;

K. Jenkins,
None;

M. Kent,
None;

S. Lambert,
None;

C. Drews-Botsch,
None;

S. Prahalad,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-new-measure-of-visual-function-for-children-with-juvenile-idiopathic-arthritis-associated-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology